hepatocellular carcinoma
Conditions
Interventions
The intervention in this study is PET/CT imaging using ^18^F-FAPI-74. This imaging technique is performed on patients with hepatocellular carcinoma before and after systemic drug therapy. Specifically
Sponsors
Kobe City Medical Center General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 18 years or older at the time of consent Diagnosed with hepatocellular carcinoma and scheduled for systemic drug therapy Consent to the use of 18F-FAPI-74 PET results in clinical practice if deemed necessary by the attending physician Ability to provide written informed consent
Exclusion criteria
Exclusion criteria: Pregnant women or those who may be pregnant Individuals with severe claustrophobia Individuals deemed unsuitable for participation in this study by the principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between the rate of change in 18F-FAPI-74 PET quantitative values for each lesion and treatment response assessment by RECIST and mRECIST criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Correlation between the rate of change in 18F-FAPI-74 PET quantitative values and the rate of change in tumor markers (AFP, PIVKA-II) 2. Comparison of pre-treatment 18F-FAPI-74 PET/CT imaging findings with those of contrast-enhanced CT and MRI | — |
Countries
Japan
Contacts
Public ContactShojiro Oka
Kobe City Medical Center General Hospital Department of Diagnostic Radiology
Outcome results
None listed